Sugi Predict

Sugi Predict / Compounds / SCHEMBL1444265

SCHEMBL1444265

SCHEMBL1444265

CCOC(=O)COc1[c]cccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.48
▸ KDM4E B2RXH2 2/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ USP2 O75604 1/20 0.47
▸ NPSR1 Q6W5P4 3/20 0.45
▸ GAA P10253 1/20 0.45
▸ HPGD P15428 3/20 0.44
▸ MAPT P10636 2/20 0.44
▸ HSD17B10 Q99714 2/20 0.44
▸ ABCB1 P08183 1/20 0.44
▸ CASP3 P42574 1/20 0.44
▸ CASP7 P55210 1/20 0.44
▸ CASP9 P55211 1/20 0.44
▸ TP53 P04637 1/20 0.44
▸ GLA P06280 1/20 0.43
▸ PTPN1 P18031 2/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ S1PR4 O95977 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ ITGA4 P13612 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2565533 0.83 KMT2A (0.40) ALDH1A1KDM4ESMN1; SMN2MAPTLMNA
SCHEMBL17048204 0.83 CYP4F2 (0.47) ALDH1A1SMN1; SMN2GAAMAPTNPC1
SCHEMBL27414359 0.82 CYP4F2 (0.49) ALDH1A1SMN1; SMN2
SCHEMBL7476145 0.80 GABRA1 (0.34) ALDH1A1KDM4ESMN1; SMN2USP2
SCHEMBL7048126 0.80 HSD11B1 (0.35) ALDH1A1SMN1; SMN2GLANPC1RAB9A
SCHEMBL11850746 0.80 KMT2A (0.39) ALDH1A1KDM4ESMN1; SMN2USP2HPGD
SCHEMBL8749753 0.79 RAB9A (0.54) ALDH1A1KDM4EGAAMAPTNPC1
SCHEMBL5177256 0.79 PTPN1 (0.39) ALDH1A1KDM4ENPSR1HPGDMAPT
SCHEMBL8749612 0.79 SMN1; SMN2 (0.51) ALDH1A1KDM4ESMN1; SMN2NPSR1GAA
SCHEMBL7716136 0.78 NPSR1 (0.44) ALDH1A1SMN1; SMN2NPSR1HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7053078-B2 Serine protease inhibitors ELI LILLY AND COMPANY (US) 2006-05-30 — — US claimed
EP-1289954-B1 SERINE PROTEASE INHIBITORS LILLY CO ELI (US) 2005-09-14 — — EP claimed
US-20050080073-A1 Sulfonylaminocarboxiylic acid N-arylamides as guanylate cyclase activators AVENTIS PHARMA DEUTSCHLAND GMBH 2005-04-14 — — US claimed
US-20030171352-A1 Sulfonylaminocarboxylic acid N-arylamides as guanylate cyclase activators AVENTIS PHARMA DEUTSCHLAND GMBH 2003-09-11 — — US claimed
EP-1194417-A1 PHENOXY FLUOROPYRIMIDINES BAYER AG (DE) 2002-04-10 — — EP claimed
EP-1095015-A2 SULFONYLAMINO CARBOXYLIC ACID N-ARYLAMIDES AS GUANYLATE CYCLASE ACTIVATORS Aventis Pharma Deutschland GmbH (DE) 2001-05-02 — — EP claimed
WO-2000078733-A1 PHENOXY FLUOROPYRIMIDINES BAYER AKTIENGESELLSCHAFT (DE) 2000-12-28 — — WO claimed
WO-2000002850-A2 SULFONYLAMINO CARBOXYLIC ACID N-ARYLAMIDES AS GUANYLATE CYCLASE ACTIVATORS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-01-20 — — WO claimed
WO-2016040081-A1 QUINAZOLINE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS JANSSEN PHARMACEUTICA NV (BE) 2016-03-17 — — WO disclosed
US-20140288127-A1 Novel Alkene Oxindole Derivatives F. HOFFMANN-LA ROCHE AG (CH) 2014-09-25 — — US disclosed
US-8778973-B2 Alkene oxindole derivatives HOFFMANN-LAROCHE INC. (US) 2014-07-15 — — US disclosed
US-20130131114-A1 NOVEL ALKENE OXINDOLE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2013-05-23 — — US disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 — — EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 — — EP disclosed
EP-1097933-A1 PYRIMIDINE DERIVATIVES EXHIBITING ANTITUMOR ACTIVITY SHIONOGI & CO., LTD. (JP) 2001-05-09 — — EP disclosed
EP-1095015-A2 SULFONYLAMINO CARBOXYLIC ACID N-ARYLAMIDES AS GUANYLATE CYCLASE ACTIVATORS Aventis Pharma Deutschland GmbH (DE) 2001-05-02 — — EP disclosed
WO-2000078733-A1 PHENOXY FLUOROPYRIMIDINES BAYER AKTIENGESELLSCHAFT (DE) 2000-12-28 — — WO disclosed
WO-2000002850-A2 SULFONYLAMINO CARBOXYLIC ACID N-ARYLAMIDES AS GUANYLATE CYCLASE ACTIVATORS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-01-20 — — WO disclosed
WO-1996016980-A1 MORPHOLINOETHYLAMIDE DERIVATIVES NOVARTIS AG (CH) 1996-06-06 — — WO disclosed
EP-0374756-A2 Nitrogen-containing cyclic compounds MERCK PATENT GmbH (DE) 1990-06-27 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080073-A1 Sulfonylaminocarboxiylic acid N-arylamides as guanylate cyclase activators GUCY1A1, GUCY1B1, GUCY1A2 ALDH1A1 511/4885KDM4E 4187/4885SMN1; SMN2 1946/4885
US-20140288127-A1 Novel Alkene Oxindole Derivatives PRKAB1, PRKAR2A, PRKAB2 ALDH1A1 334/4885KDM4E 1757/4885SMN1; SMN2 2317/4885
US-20030171352-A1 Sulfonylaminocarboxylic acid N-arylamides as guanylate cyclase activators GUCY1A1, GUCY1B1, GUCY1B2 ALDH1A1 899/4885KDM4E 3666/4885SMN1; SMN2 2314/4885
US-20130131114-A1 NOVEL ALKENE OXINDOLE DERIVATIVES PRKAB1, PRKAR2A, PRKAB2 ALDH1A1 334/4885KDM4E 1757/4885SMN1; SMN2 2317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.